Who are Comparator: Aprepitant's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fosaprepitant for Injection, Aprepitant plus Ondansetron, Dexamethasone, Ondansetron, Aprepitant, Akynzeo solution, fosnetupitant/ palonosetron, EMEND.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/comparator-aprepitant.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Comparator: Aprepitant — Competitive Intelligence Brief

Comparator: Aprepitant (Comparator: Aprepitant) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neurokinin-1 (NK1) receptor antagonist. Area: Oncology.

phase 3 Neurokinin-1 (NK1) receptor antagonist NK1 receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Comparator: Aprepitant (Comparator: Aprepitant) — Merck Sharp & Dohme LLC. Aprepitant is a neurokinin-1 (NK1) receptor antagonist that blocks substance P signaling in the chemoreceptor trigger zone and vomiting center to prevent nausea and vomiting.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Comparator: Aprepitant TARGET	Comparator: Aprepitant	Merck Sharp & Dohme LLC	phase 3	Neurokinin-1 (NK1) receptor antagonist	NK1 receptor
Fosaprepitant for Injection	Fosaprepitant for Injection	Montefiore Medical Center	marketed	NK1 receptor antagonist	NK1 receptor (neurokinin-1 receptor)
Aprepitant plus Ondansetron	Aprepitant plus Ondansetron	University of Pittsburgh	marketed	NK1 receptor antagonist + 5-HT3 receptor antagonist combination	NK1 receptor (aprepitant); 5-HT3 receptor (ondansetron)
Dexamethasone, Ondansetron, Aprepitant	Dexamethasone, Ondansetron, Aprepitant	Ottawa Hospital Research Institute	marketed	Antiemetic combination (corticosteroid + 5-HT3 antagonist + NK1 antagonist)	Glucocorticoid receptor, 5-HT3 receptor, NK1 receptor
Akynzeo solution	Akynzeo solution	Helsinn Healthcare SA	marketed	NK1 receptor antagonist / 5-HT3 receptor antagonist combination	NK1 receptor (netupitant component); 5-HT3 receptor (palonosetron component)
fosnetupitant/ palonosetron	fosnetupitant/ palonosetron	Helsinn Healthcare SA	marketed	NK1 receptor antagonist / 5-HT3 receptor antagonist combination	NK1 receptor (substance P receptor) / 5-HT3 receptor
EMEND	EMEND	Merck Sharp & Dohme LLC	marketed	Neurokinin-1 (NK1) receptor antagonist	NK1 receptor (neurokinin-1 receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neurokinin-1 (NK1) receptor antagonist class)

Merck Sharp & Dohme LLC · 4 drugs in this class
Organon and Co · 2 drugs in this class
Allergan · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Comparator: Aprepitant — Competitive Intelligence Brief. https://druglandscape.com/ci/comparator-aprepitant. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab